Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2Article Published on 2024-12-312024-09-02 Journal: Pharmeur Bio Sci Notes [Category] 파상풍, [키워드] European Pharmacopoeia international standard potency Quality control reference standard Tetanus immunoglobulin PMC 바로가기
Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2Article Published on 2024-12-312024-09-02 Journal: Pharmeur Bio Sci Notes [Category] 파상풍, [키워드] European Pharmacopoeia international standard potency Quality control reference standard Tetanus immunoglobulin PMC 바로가기
Effect of 3D and 2D cell culture systems on trophoblast extracellular vesicle physico-chemical characteristics and potencyarticle Published on 2024-05-212024-09-05 Journal: Frontiers in Cell and Developmental Biology [Category] update2024, [키워드] cell culture systems embryo implantation Extracellular vesicles potency three dimensional two dimensional [DOI] 10.3389/fcell.2024.1382552 PMC 바로가기 [Article Type] article
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 InfectionsArticle Published on 2024-04-222024-09-05 Journal: Viruses [Category] update2024, [키워드] Antiviral agents coronavirus COVID-19 Drug repurposing pharmacokinetics potency potential efficacy SARS-CoV-2 [DOI] 10.3390/v16040651 PMC 바로가기 [Article Type] Article
Development of a monoclonal antibody sandwich ELISA for the determination of antigen content and quality in diphtheria vaccines디프테리아 백신에서 항원 함량 및 품질을 측정하기 위한 단클론 항체 샌드위치 ELISA 개발Article Published on 2024-01-092024-08-19 Journal: ALTEX [Category] 파상풍, [키워드] 3Rs consistency approach immunoassay potency Vaccine
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concernArticle Published on 2022-09-182022-10-06 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] absence ACE2 acute respiratory syndrome ADK antibody BA.2 BA.5 Beta BNT162b2 breadth Breakthrough infection cell line change circulating clade Clinical effect cohorts contributed convalescent convalescent sera coronavirus COVID-19 COVID-19 hospitalisation Delta development disease severity Donor donors dose foundation Future genetic difference greater humoral Humoral response IgG in vitro isolate Lineage lineages Live virus management monitoring monoclonal antibody mortality rates nafamostat nasopharyngeal sample nasopharyngeal swabs neutralisation neutralisation assay Neutralising Antibodies neutralising antibody New observation of BNT162b2 omicron Omicron BA.1 other variant pathway peak plasma potency recorded reduced reduction reduction in Research response responses SARS-CoV-2 sensitivity significantly Sotrovimab South Spread Support supported tested Testing therapeutic Therapies TMPRSS2 TMPRSS2 inhibitor Transmission utilised vaccination Vaccine variant viral lineage viral variant [DOI] 10.1016/j.ebiom.2022.104270 PMC 바로가기 [Article Type] Article
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devicesCOVID-19에 대한 흡입 요법: 약물, 제형 및 장치에 대한 고려 사항Review Published on 2022-08-252022-09-11 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Administered administration anti-SARS-CoV-2 antiviral drug antiviral drugs Antiviral treatment approach Clinical studies Combinational Concentration coronavirus COVID-19 COVID-19 pandemic Device disease dose drug drug combination drug susceptibility drugs effective effective vaccine Efficacy etiological agent include Infection inhalation Inhaled intravenous key consideration limitations lower dose lung majority mono potency preclinical studies reduce reduced responsible SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown Side effects tested therapy Treatment treatment for COVID-19 [DOI] 10.1016/j.ijpharm.2022.122042 PMC 바로가기 [Article Type] Review
Interferon resistance of emerging SARS-CoV-2 variants새로운 SARS-CoV-2 변이체의 인터페론 내성Article Published on 2022-08-092022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] (Alpha) (Beta) Alpha B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta Course COVID-19 COVID-19 pandemic Critical driving ENhance exhibited FIVE highlight implication include infections Innate immunity interferon interferon response interferons isolates lethality limit lineages Mutation neutralizing antibody outbreak P.1 Pathogenesis potency responses SARS-CoV-2 SARS-CoV-2 evolution SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants spike spike mutations subtype the interferon Transmissibility Treatment Vaccine variant variants variants of concern Viral viral gene viral genes viral lineage virus infectivity while [DOI] 10.1073/pnas.2203760119 PMC 바로가기 [Article Type] Article
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster modelSARS-CoV-2 VOC 유형 및 생물학적 성별은 중증 COVID-19 드워프 햄스터 모델에서 몰누피라비르 효능에 영향을 미칩니다Article Published on 2022-07-292022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료법, 치료제, [키워드] Affect Antiviral benefit Cell disease effect size Efficacy evaluate females ferret ferrets hamster highest Human airway epithelium IMPROVE in vivo Infection inhibited lung Lung injury magnitude males management molnupiravir omicron oral organoids pathogenicity potency prevented reduced reduction in SARS-CoV-2 SARS-CoV-2 variants severe COVID-19 Sex survived Transmission Treatment effect size Trial triggered variants of concern virus load VoC [DOI] 10.1038/s41467-022-32045-1 PMC 바로가기 [Article Type] Article
Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants신규 설계된 SARS-CoV-2 HR1 삼량체, SARS-CoV-2 및 그 변이체에 대해 향상된 효능 및 광범위한 활성을 나타냄Article Published on 2022-07-132022-09-11 Journal: Journal of Virology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] activities activity adopted affinity antibodies binding affinity C terminus caused cell-cell fusion develop domain effective Effectiveness foldon foundation fusing fusion fusion inhibitor global public health HR1 HR1 domain Improved increased the risk information inhibit inhibit SARS-CoV-2 inhibitor inhibitors inhibitory inhibitory activity limit MERS MERS-CoV MERS-CoV pseudoviruses motif much higher Multiple NAbs Neutralizing antibodies neutralizing antibody novel pandemic of COVID-19 peptide Peptide inhibitor Peptide Inhibitors peptides potency provide pseudoviruses reported S protein SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants shown significantly Spread the S protein the SARS-CoV-2 theory treating SARS-CoV-2 infection trimer trimeric Vaccine variants viral infection viral S protein viral variant Viral variants VOCs [DOI] 10.1128/jvi.00681-22 PMC 바로가기 [Article Type] Article